NASDAQ · MDCXW
Healthcare · Biotechnology
$0.21
Up+$0.01 (+4.76%)
Updated Nov 5, 2026, 3:47 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · MDCXW
1M range · 11 trading sessions · Daily adjusted prices
Prices through Nov 2, 2026
MDCXW closed at $0.21 after 11 trading sessions, down 27.59% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 2, 2026 | $0.23 | $0.23 | $0.21 | $0.21 | 410.89 |
| Oct 30, 2026 | $0.21 | $0.21 | $0.21 | $0.21 | 250 |
| Oct 29, 2026 | $0.21 | $0.2101 | $0.21 | $0.21 | 1.31K |
| Oct 27, 2026 | $0.3383 | $0.3383 | $0.24 | $0.24 | 664.71 |
| Oct 23, 2026 | $0.27 | $0.27 | $0.27 | $0.27 | 500 |
| Oct 21, 2026 | $0.21 | $0.2101 | $0.21 | $0.21 | 602 |
| Oct 19, 2026 | $0.20 | $0.20 | $0.20 | $0.20 | 2.37K |
| Oct 16, 2026 | $0.12 | $0.29 | $0.12 | $0.26 | 2.43K |
| Oct 15, 2026 | $0.25 | $0.25 | $0.20 | $0.20 | 1.29K |
| Oct 13, 2026 | $0.299 | $0.299 | $0.299 | $0.299 | 720.97 |
| Oct 9, 2026 | $0.3405 | $0.365 | $0.0111 | $0.29 | 2.46K |
The latest Smart Investors Daily articles mentioning MDCXW.
Company
Market Activity
Research & News
MDCXW research
Company profile and research snapshot.
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
Visit company websiteConsensus and target data currently published for this company.
No generated briefing is available yet.
Yahoo · Oct 27, 2026
Medicus Pharma (NASDAQ:MDCX) CEO Dr Raza Bokhari will present at BioFuture 2026 in New York and deliver a keynote at the Global Biotechnology Summit 2026 in Abu Dhabi. Bokhari will join a BioFuture panel today titled “Beyond the Cure: The Brave New World of Revolutionary Cancer...
Yahoo · Oct 27, 2026
Company’s Executive Chairman and CEO to Speak on Cancer Therapeutics Spotlight Panel at BioFuture in NYC and Deliver Keynote Address at Global Biotechnology Summit in Abu DhabiPHILADELPHIA, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that Dr. Raza Bokhari, Executive Chairman and Chief Executive Officer,
Yahoo · Oct 26, 2026
Nasdaq closes the minimum bid price matter confirming that the Company has regained compliancePHILADELPHIA, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) (“Medicus” or the “Company”), a precision guided, biotech/life sciences company focused on advancing novel and potentially disruptive therapeutic assets, today announced that it received written notice on October 23, 2026 (the “Compliance Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (
Yahoo · Oct 8, 2026
Medicus Pharma is prioritizing clinical milestones, regulatory progress and potential partnerships across its oncology, dermatology and urology portfolio as it seeks to demonstrate returns on three years of investment. Key Investor TakeawaysMedicus Pharma (NASDAQ:MDCX) has raised approximately $90 million through equity and debt financing over three years, supporting acquisitions, clinical development and operations.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MDCXW.
No results
No recent SID articles mention MDCXW.
